AXIL Brands Q1 Revenue Falls 11.2% as XCOR II Orders Hit $3.6M

AXIL Brands, Inc. reported first quarter fiscal 2027 net revenues of $6.1 million for the period ended August 31, 2026, an 11.2% decline from $6.9 million a year earlier, according to results the company announced on October 6, 2026. Gross profit rose to $5.0 million, or 82.6% of sales, from $4.6 million, or 67.6%, and net income came in at $0.4 million, or $0.05 per diluted share, versus $0.3 million, or $0.04. Cash reached $7.9 million with no outstanding borrowings.

Context — Why AXIL's Q1 Revenue Drop Matters Now

The revenue decline is not a demand collapse. The company attributed the shortfall to two specific items: the planned transition from its first-generation XCOR wireless earbud to XCOR II, and a material big-box order in the prior-year quarter that did not repeat.

That distinction matters for anyone reading the headline number. AXIL's direct-to-consumer hearing segment revenue fell less than 1%, which the company framed as evidence that underlying demand held while wholesale timing shifted.

The company announced XCOR II on August 26, 2026, with availability beginning September 15, 2026. Initial orders exceeded $2.8 million as of the announcement date and $3.6 million as of September 30, 2026, spanning retail, distribution, and direct-to-consumer channels.

First-quarter results absorbed roughly $360,000 in advertising costs plus inventory staging tied to the launch. None of that spending or shipment activity converted to first-quarter revenue, and the company said it expects both to land in the second quarter.

AXIL also moved on its Reviv3 hair and skin care brand, bringing three strategic partners into Reviv3 ProCare Company to lead a planned global relaunch. The partners received approximately 25% ownership in aggregate, valued at $137,511 and recorded as a non-cash first-quarter expense. AXIL retains roughly 75% and continues to consolidate Reviv3 results.

Data — What the Numbers Show

The margin picture needs one adjustment before it reads clean. Reported gross margin of 82.6% included a non-recurring $0.55 million benefit from IEEPA customs duty refunds recognized as a reduction of cost of revenues. Excluding that item, gross margin was approximately 73.6%.

Metric	Q1 FY2027	Q1 FY2026
Net revenues	$6,090,383	$6,856,218
Gross profit	$5,031,729	$4,634,934
Gross margin (reported)	82.6%	67.6%
Income from operations	$437,027	$411,738
Net income	$420,571	$334,294
Adjusted EBITDA	$826,841	$674,355
Adjusted EBITDA margin	13.6%	9.8%
Cash and equivalents	$7,928,587	$4,086,624

Operating income improved to $437,027 from $411,738 even on lower revenue, helped by cost of revenues falling to $1.06 million from $2.22 million. Research and development went from zero in the prior-year quarter to $459,631.

Adjusted EBITDA rose to $826,841 from $674,355, lifting adjusted EBITDA margin to 13.6% from 9.8%. The company defines adjusted EBITDA as EBITDA further adjusted for stock-based compensation, which totaled $322,393 in the quarter against $199,212 a year earlier.

Cash flow flipped hard. Net cash provided by operating activities was $3.8 million, against $739,000 used in the prior-year period, driven largely by a $3.45 million reduction in accounts receivable.

The balance sheet strengthened alongside it. Cash rose to $7.9 million as of August 31, 2026 from $4.5 million as of May 31, 2026, with total current assets of $14.7 million and total liabilities of $4.7 million. Inventory was essentially flat at $4.4 million.

AXIL received $0.9 million in IEEPA customs duty refunds including interest from U.S. Customs and Border Protection. Of that, $0.55 million related to products already sold and reduced cost of revenues, $0.32 million related to inventory still on hand and reduced inventory, and $0.04 million was interest booked in other income. The company said no IEEPA refund claims remain outstanding.

Analysis — What It Means for AXIL and Consumer Product Peers

AXIL sits in a narrow slice of the consumer products market: premium hearing enhancement and protection under the AXIL brand, plus hair and skincare under Reviv3. Both compete against far larger balance sheets, which makes the company's cash position and lack of borrowings the operative fact here.

A quarter that produces $3.8 million of operating cash inflow while revenue declines 11.2% tells a working-capital story. The $3.45 million accounts receivable collection is the mechanical driver, and it reflects the prior quarter's sales converting to cash rather than new demand.

The XCOR II order book is the forward-looking number the market will price. The company said shipments are underway in the second quarter of fiscal 2027, and that by September 30, 2026 it had fulfilled the majority of the XCOR II order backlog.

The obvious counter-argument is conversion risk. Orders are not revenue, and the company's own forward-looking statements flag that order cancellations and returns could affect the XCOR II launch. A $3.6 million order book that ships partially or returns partially changes the second-quarter picture materially.

Reviv3 adds a second variable. AXIL brought in partners without deploying AXIL cash, but the 25% dilution of a consolidated subsidiary means a larger share of any Reviv3 losses now sits with outside holders. The first quarter showed a $1,021 net loss of subsidiary attributable to noncontrolling interests.

Positioning is straightforward to infer from the disclosures. Investors holding AXIL are effectively long a launch story with a funded balance sheet; anyone short the name is betting the XCOR II order book fails to convert or that the prior-year big-box order was structural rather than timing.

Outlook — What to Watch Next

Three items carry the next two quarters. First, second-quarter revenue, which the company said should reflect the XCOR II launch investment and orders. Second, the pace at which the remaining XCOR II backlog ships, given the company's statement that the majority was fulfilled by September 30, 2026. Third, any further detail on the Reviv3 relaunch timeline, which the company has not dated.

The company did not issue numerical revenue or earnings guidance in the release, so there is no stated target to measure against. Investors looking for a benchmark will instead track the $3.6 million order figure against reported second-quarter hearing segment revenue.

Margin is the other line to watch. Underlying gross margin of 73.6% is the number to carry forward, since the 82.6% reported figure included the one-time customs refund and the company confirmed no claims remain outstanding.

AXIL hosted a conference call at 5:00 PM ET on October 6, 2026, with a telephone replay available for seven days using access code 13762995.

Frequently Asked Questions

Why did AXIL Brands revenue fall 11.2% in the first quarter?

The company pointed to two causes. It planned the transition away from first-generation XCOR toward XCOR II, which slowed sales of the older product, and a large big-box order placed in the prior-year quarter did not repeat. Direct-to-consumer hearing revenue fell less than 1%, which the company cited as evidence that underlying demand held.

What does the $3.6 million XCOR II order figure actually represent?

It is the cumulative value of orders received as of September 30, 2026, up from more than $2.8 million as of the August 26 announcement. Orders are not recognized revenue. The company said shipments began in the second quarter of fiscal 2027 and that it had fulfilled the majority of the backlog by September 30.

How did AXIL's cash position change during the quarter?

Cash rose to $7.9 million on August 31, 2026 from $4.5 million on May 31, 2026, with no outstanding borrowings. Operating activities provided $3.8 million, compared with $739,000 used a year earlier, mainly because accounts receivable fell by $3.45 million. The company also collected $0.9 million in IEEPA customs duty refunds including interest.

Bottom Line

AXIL's revenue fell on timing, not demand, and $7.9 million of debt-free cash funds the XCOR II bet.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.